Fax: (646) 888-1910
Chemotherapy-induced peripheral neuropathy
Version of Record online: 6 APR 2012
Copyright © 2012 American Cancer Society
Supplement: A Prospective Surveillance Model for Rehabilitation for Women With Breast Cancer
Volume 118, Issue Supplement 8, pages 2250–2260, 15 April 2012
How to Cite
Stubblefield, M. D., McNeely, M. L., Alfano, C. M. and Mayer, D. K. (2012), A prospective surveillance model for physical rehabilitation of women with breast cancer. Cancer, 118: 2250–2260. doi: 10.1002/cncr.27463
The articles in this supplement were commissioned based on presentations and deliberations at a Roundtable Meeting on a Prospective Model of Care for Breast Cancer Rehabilitation, held February 24-25, 2011, at the American Cancer Society National Home Office, in Atlanta, Georgia.
The opinions or views expressed in this supplement are those of the authors, and do not necessarily reflect the opinions or recommendations of the editors or the American Cancer Society.
A Prospective Surveillance Model for Rehabilitation for Women with Breast Cancer, Supplement to Cancer.
Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms
- Issue online: 6 APR 2012
- Version of Record online: 6 APR 2012
- Manuscript Accepted: 7 NOV 2011
- Manuscript Received: 17 OCT 2011
- Manuscript Revised: 14 SEP 2011
- brachial plexopathy;
- breast cancer;
- palliative care
Chemotherapy-induced peripheral neuropathy (CIPN) results from damage to or dysfunction of the peripheral nerves. The development of CIPN is anticipated for the majority of breast cancer patients who receive neurotoxic chemotherapy, depending on the agent used, dose, and schedule. Sensory symptoms often predominate and include numbness, tingling, and distal extremity pain. Weakness, gait impairment, loss of functional abilities, and other deficits may develop with more severe CIPN. This article outlines a prospective surveillance model for physical rehabilitation of women with breast cancer who develop CIPN. Rehabilitative efforts for CIPN start at the time of breast cancer diagnosis and treatment planning. The prechemotherapy evaluation identifies patients with preexisting peripheral nervous system disorders that may place them at higher risk for the development of CIPN. This clinical evaluation should include a history focusing on symptoms and functional activities as well as a physical examination that objectively assesses the patient's strength, sensation, reflexes, and gait. Ongoing surveillance following the initiation of a neurotoxic agent is important to monitor for the development and progression of symptoms associated with CIPN, and to ensure its resolution over the long term. CIPN is managed best by a multidisciplinary team approach. Early identification of symptoms will ensure appropriate referral and timely symptom management. The prospective surveillance model promotes a patient-centered approach to care, from pretreatment through survivorship and palliative care. In this way, the model offers promise in addressing and minimizing both the acute and long-term morbidity associated with CIPN. Cancer 2012;. © 2012 American Cancer Society.